Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.

ABSTRACT:

Purpose

In this review, we have highlighted a new class of drugs, Bruton's tyrosine kinase (BTK) inhibitors, and summarized the results of recent clinical trials in the treatment of multiple sclerosis.

Views

Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system, in which B-lymphocytes and myeloid cells, such as macrophages and microglia, play an important role in the pathogenesis. B-cells induce pathological processes by presenting autoantigens to T-lymphocytes, secreting pro-inflammatory cytokines, and forming ectopic lymphoid follicle-shaped clusters. Accordingly, the activation of microglia contributes to the development of chronic inflammation due to the production of chemokines, cytokines, reactive oxygen, and nitrogen species. BTK is

SUBMITTER: Shulga O 

PROVIDER: S-EPMC10243295 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature